Quantcast

Latest American Association for the Study of Liver Diseases Stories

2009-11-02 16:30:00

BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1. In the lead-in arms of the study, in which patients received a 4-week lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin,...

2009-11-02 10:44:00

ALEXANDRIA, Va. and BOSTON, Nov. 2 /PRNewswire/ -- All approved therapy regimens to treat patients with hepatitis C are based on interferon, which must be injected. In this clinical trial to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers treated patients - both treatment naive and experienced patients - with a twice daily oral combination therapy of a nucleoside polymerase and protease inhibitor. The results were significant...

2009-11-02 07:00:00

BOSTON, Nov. 2 /PRNewswire/ -- UCL Liver Failure Group presented data from two studies with OCR-002 (L-ornithine phenylacetate) that suggest the potential for this novel therapeutic agent to impact multiple aspects of liver disease and its complications. OCR-002 is licensed to Ocera Therapeutics, Inc. of San Diego, California. The data, presented at the 60th annual meeting of the American Association for the Study of Liver Diseases, is comprised of a set of studies evaluating the...

2009-11-02 07:00:00

BOSTON, Nov. 2 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that AST-120 (spherical carbon adsorbent) was shown to reduce the severity of pruritus (itching) in patients with chronic liver disease. The data were presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases in a presentation titled, "Oral AST-120 (Spherical Carbon Adsorbent) Improves Pruritus and Lowers Serum Bile Acids in Patients with Cirrhosis of Various Etiologies." These...

2009-11-01 16:00:00

BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in patients with chronic hepatitis C virus (HCV) genotype 1. These retrospective analyses were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3. Boceprevir is an investigational HCV protease inhibitor. Phase III registration...

2009-11-01 06:03:41

Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study. "We found that patients who achieved a sustained virological response were more likely to have had extended treatment," says Kimberly Brown, M.D., Division head of Gastroenterology at Henry Ford Hospital and senior author of the study. "In addition,...

2009-10-29 10:42:00

ALEXANDRIA, Va. and BOSTON, Oct. 29 /PRNewswire/ -- Although women with chronic hepatitis C virus (HCV) infection are at lower risk for developing cirrhosis, researchers who compared outcomes for men and women after having liver transplantation found that women have a significantly increased risk of overall graft loss and graft loss from recurrent HCV than men. "Given the higher rate of graft losses due to recurrent HCV and higher risk of developing advanced HCV, our results highlight the...

2009-10-28 10:41:00

ALEXANDRIA, Va., and BOSTON, Oct. 28 /PRNewswire/ -- The final results of the PROVE3 study will be presented at this year's annual meeting of the American Association for the Study of Liver Diseases. This phase 2 study was of telaprevir compared to a combination therapy of peginterferon alfa-2a and ribavirin. It intended to measure the 6 month and also 1-year durability of sustained viral response in genotype 1 patients with HCV who failed prior treatment with pegylated interferon and...

2009-10-27 11:02:00

WASHINGTON and BOSTON, Oct. 27 /PRNewswire/ -- Commercially available multivitamin preparations commonly given to infants with biliary atresia to prevent fat soluble vitamin deficiencies are ineffective, according to researchers presenting at the 2009 annual meeting of the American Association for the Study of Liver Diseases. "This study examined a multivitamin preparation, which if often used by clinicians due to the convenience and perception that it is effective, however, there are...

2009-10-16 11:25:00

BOSTON, Oct. 16 /PRNewswire/ -- AASLD President Scott L. Friedman, MD, will host a press conference on the first full day of presentations at the Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases. When: Saturday, October 31, 2009 - 4:00-5:00 pm Where: Hynes Convention Center, Room 209, Boston Dr. Friedman will highlight individual studies and themes from the almost 2000 abstracts to be presented at this year's meeting from...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related